NASDAQ:ARDSAridis Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aridis Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.85 +0.73 (+10.25 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$7.33Now: $7.85▼$7.8850-Day Range$6.16MA: $6.86▼$7.6152-Week Range$3.80Now: $7.85▼$12.40Volume303 shsAverage Volume12,728 shsMarket Capitalization$70.02 millionP/E RatioN/ADividend YieldN/ABeta0.07 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInstitutional OwnershipHeadlinesShort InterestSocial Media Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in San Jose, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAridis Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.60, Aridis Pharmaceuticals has a potential upside of 111.5% from its current price of $7.85.Amount of Analyst CoverageAridis Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesAridis Pharmaceuticals has received 109 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAridis Pharmaceuticals has received 126 “underperform” votes. (Add your “underperform” vote.)Community SentimentAridis Pharmaceuticals has received 53.62% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aridis Pharmaceuticals and other stocks. Vote “Outperform” if you believe ARDS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARDS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAridis Pharmaceuticals does not currently pay a dividend.Dividend GrowthAridis Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aridis Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 20.85% of the stock of Aridis Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 1.07% of the stock of Aridis Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aridis Pharmaceuticals are expected to grow in the coming year, from ($3.02) to ($2.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aridis Pharmaceuticals is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aridis Pharmaceuticals is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAridis Pharmaceuticals has a P/B Ratio of 19.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.29 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARDS Previous Symbol CUSIPN/A CIKN/A Webwww.aridispharma.com Phone408-385-1742Debt Debt-to-Equity RatioN/A Current Ratio1.03 Quick Ratio1.03Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.02 million Price / Sales68.65 Cash FlowN/A Price / Cash FlowN/A Book Value$0.41 per share Price / Book19.15Profitability EPS (Most Recent Fiscal Year)($3.51) Net Income$-29,680,000.00 Net MarginsN/A Return on Equity-538.27% Return on Assets-112.25%Miscellaneous Employees25 Outstanding Shares8,920,000Market Cap$70.02 million Next Earnings Date8/10/2020 (Estimated) OptionableNot Optionable $7.85 +0.73 (+10.25 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ARDS News and Ratings via Email Sign-up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter. Aridis Pharmaceuticals (NASDAQ:ARDS) Frequently Asked Questions How has Aridis Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Aridis Pharmaceuticals' stock was trading at $6.46 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ARDS stock has increased by 21.5% and is now trading at $7.85. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Aridis Pharmaceuticals? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aridis Pharmaceuticals. When is Aridis Pharmaceuticals' next earnings date? Aridis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Aridis Pharmaceuticals. How were Aridis Pharmaceuticals' earnings last quarter? Aridis Pharmaceuticals Inc (NASDAQ:ARDS) released its quarterly earnings data on Tuesday, May, 12th. The company reported ($0.73) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.67) by $0.06. View Aridis Pharmaceuticals' earnings history. What price target have analysts set for ARDS? 5 analysts have issued 1 year price objectives for Aridis Pharmaceuticals' shares. Their forecasts range from $11.00 to $22.00. On average, they anticipate Aridis Pharmaceuticals' share price to reach $16.60 in the next year. This suggests a possible upside of 111.5% from the stock's current price. View analysts' price targets for Aridis Pharmaceuticals. Has Aridis Pharmaceuticals been receiving favorable news coverage? Headlines about ARDS stock have been trending negative on Saturday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Aridis Pharmaceuticals earned a daily sentiment score of -2.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Aridis Pharmaceuticals. Are investors shorting Aridis Pharmaceuticals? Aridis Pharmaceuticals saw a decline in short interest in July. As of July 31st, there was short interest totaling 26,200 shares, a decline of 6.1% from the July 15th total of 27,900 shares. Based on an average daily trading volume, of 10,600 shares, the short-interest ratio is currently 2.5 days. Currently, 0.5% of the shares of the stock are short sold. View Aridis Pharmaceuticals' Short Interest. Who are some of Aridis Pharmaceuticals' key competitors? Some companies that are related to Aridis Pharmaceuticals include Lannett (LCI), Northwest Biotherapeutics (NWBO), Fortress Biotech (FBIO), Verastem (VSTM), IDEAYA Biosciences (IDYA), Abeona Therapeutics (ABEO), Hookipa Pharma (HOOK), Agile Therapeutics (AGRX), Five Prime Therapeutics (FPRX), Selecta Biosciences (SELB), IVERIC bio (ISEE), OrganiGram (OGI), Strongbridge Biopharma (SBBP), Milestone Pharmaceuticals (MIST) and NuCana (NCNA). View all competitors. What other stocks do shareholders of Aridis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aridis Pharmaceuticals investors own include Juno Therapeutics (JUNO), Gilead Sciences (GILD), VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Inovio Pharmaceuticals (INO), Sanofi (SNY), Dynavax Technologies (DVAX), (MRNA), Matinas BioPharma (MTNB) and Ocular Therapeutix (OCUL). Who are Aridis Pharmaceuticals' key executives? Aridis Pharmaceuticals' management team includes the following people: Dr. Eric J. Patzer, Exec. Chairman (Age 71, Pay $233.12k)Dr. Vu L. Truong, Founder, CEO & Director (Age 56, Pay $652.5k)Mr. Fred Kurland, Consultant (Age 69, Pay $226.19k)Mr. Michael A. Nazak, Chief Financial Officer (Age 61)Mr. Jeffrey J. Fessler Esq., J.D., Acting Gen. Counsel (Age 57) When did Aridis Pharmaceuticals IPO? (ARDS) raised $28 million in an initial public offering (IPO) on Tuesday, August 14th 2018. The company issued 2,000,000 shares at a price of $13.00-$15.00 per share. Cantor served as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers. What is Aridis Pharmaceuticals' stock symbol? Aridis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARDS." How do I buy shares of Aridis Pharmaceuticals? Shares of ARDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Aridis Pharmaceuticals' stock price today? One share of ARDS stock can currently be purchased for approximately $7.85. How big of a company is Aridis Pharmaceuticals? Aridis Pharmaceuticals has a market capitalization of $70.02 million and generates $1.02 million in revenue each year. The company earns $-29,680,000.00 in net income (profit) each year or ($3.51) on an earnings per share basis. Aridis Pharmaceuticals employs 25 workers across the globe. What is Aridis Pharmaceuticals' official website? The official website for Aridis Pharmaceuticals is www.aridispharma.com. How can I contact Aridis Pharmaceuticals? Aridis Pharmaceuticals' mailing address is 5941 Optical Ct, San Jose CA, 95138. The company can be reached via phone at 408-385-1742 or via email at [email protected] This page was last updated on 8/8/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
